Karyopharm Therapeutics KPTI
NASDAQ KPTI
$0.41 +0.05 (+13.83%)
As of: Oct 21, 2026 · 3:19 PM EDT

Karyopharm Therapeutics (KPTI) Receivables - Other (2016)

Updated

Karyopharm Therapeutics (KPTI) recorded Receivables - Other of $154,000 in Q4 2016.

Analysis

Karyopharm Therapeutics (KPTI) Receivables - Other (2016) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,137.48 Bn 1,106.07 Bn 19.71 Bn
2 Johnson & Johnson 618.81 Bn 537.34 Bn 17.26 Bn
3 AbbVie 502.02 Bn 475.14 Bn 12.70 Bn
4 Merck 368.25 Bn 322.63 Bn 12.21 Bn
5 Novartis Ag 297.87 Bn 261.86 Bn 11.24 Bn
6 Astrazeneca 260.90 Bn 234.58 Bn 12.86 Bn
7 Amgen 236.67 Bn 192.07 Bn 7.24 Bn
8 Gilead Sciences 191.16 Bn 165.36 Bn 6.22 Bn
9 Pfizer 169.69 Bn 116.34 Bn 10.94 Bn
10 Karyopharm Therapeutics 11.81 Mn -214.61 Mn 32.35 Mn
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2016 154,000.00
API Access

Karyopharm Therapeutics Receivables - Other API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=receivables-other&ticker=KPTI&period=max&api_key=YOUR_API_KEY